A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...

When Beyfortus was approved over the summer, AstraZeneca and Sanofi, the two companies that manufacture the drug, said it would be available for babies in time for RSV season this year.

AstraZeneca’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...

The new shot, which goes by the brand name Beyfortus, slashed infants’ risk of being hospitalized for RSV by 80% in clinical trials. It promised to be a game-changer for the youngest patients.

Beyfortus contains the active ingredient nirsevimab-alip,* and Synagis contains palivizumab. If you have other questions about how Beyfortus and Synagis compare, talk with your child’s doctor.

The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its co-primary endpoints, demonstrating that BEYFORTUS provides protection for babies ...

Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe, and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.

That means that if pediatricians have only VFC-supplied Beyfortus in stock and need a dose for a baby who is not eligible for VFC coverage, they could use the dose, so long as they replace it.

The CDC and FDA have approved the Beyfortus antibody shot, from drugmakers AstraZeneca and Sanofi, to prevent respiratory syncytial virus in babies from birth to 8 months old, or in children up to ...

Parental trust in clinicians drove RSV vaccine uptake, while confusion and limited access to reliable information hindered ...

When Beyfortus was approved over the summer, AstraZeneca and Sanofi, the two companies that manufacture the drug, said it would be available for babies in time for RSV season this year.